<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494505</url>
  </required_header>
  <id_info>
    <org_study_id>P110148</org_study_id>
    <nct_id>NCT02494505</nct_id>
  </id_info>
  <brief_title>Interest of Mycophenolate for CIDP Weaning</brief_title>
  <acronym>MYCOPID</acronym>
  <official_title>Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to study if the mycophenolate could decrease the proportion of patients&#xD;
      who relapse during the IVIG tapering period and after the IVIG withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives are :&#xD;
&#xD;
        -  Study if the mycophenolate could improve the proportion of withdrew patients.&#xD;
&#xD;
        -  Study if the mycophenolate could improve the reduction of IVIG dose or could prolong the&#xD;
           interval between two courses of IVIG compared to the baseline interval at month 12 and&#xD;
           month 24 (= sparing treatment criteria).&#xD;
&#xD;
        -  Study if mycophenolate could short the delay to perform the IVIG withdrawal.&#xD;
&#xD;
        -  Study if mycophenolate could improve the clinical scores (ONLS, R-ODS MRC, INCAT&#xD;
           sensory, 10 meters test) or pain score at month 12 and month 24.&#xD;
&#xD;
        -  Study if mycophenolate could improve the quality of life at month12 and month 24.&#xD;
&#xD;
        -  Identify clinical, biological and electrophysiological factors associated with&#xD;
           withdrawal.&#xD;
&#xD;
        -  To assess the pharmacokinetics factors (Area under the curve measuring the exposure to&#xD;
           mycophenolate) and the pharmacogenetic factors (cytochrome and carrier, FcgammaR)&#xD;
           associated with withdrawal.&#xD;
&#xD;
        -  Evaluate the tolerance of Mycophenolate in this new indication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2013</start_date>
  <completion_date type="Actual">May 9, 2018</completion_date>
  <primary_completion_date type="Actual">May 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of a relapse during the tapering off period</measure>
    <time_frame>up to 18 months</time_frame>
    <description>occurrence of a relapse during the tapering off period (up to 18 months after baseline) or after the withdrawal during the monitoring period.&#xD;
(the withdrawal is defined by the ability to reach the last day of IVIG treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of withdrew patients</measure>
    <time_frame>6 months after the withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of withdrew patients at the end of the study</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sparing treatment (composite criteria)</measure>
    <time_frame>24 months</time_frame>
    <description>extension of the mean interval between IVIG courses at month 12 and month 24 compared to baseline, reduction of the total cumulative dose of IVIG at month 12 and month 24 in the mycophenolate group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the withdrawal</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVA pain score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVA pain score</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ONLS scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ONLS scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R-ODS scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R-ODS scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRC scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRC scale</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INCAT sensory test</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INCAT sensory test</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 meters test</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 meters test</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nottingham scale</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nottingham scale</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global cost</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of the global cost in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyradiculopathy</condition>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>2g/day per os</description>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patient older than eighteen&#xD;
&#xD;
          -  Written informed consent for study participation&#xD;
&#xD;
          -  Definite or probable CIDP according to EFNS/PNS criteria or atypical CIDP (need to&#xD;
             meet clinical EFNS/PNS criteria and at least 2 criteria among the EFNS/PNS&#xD;
             supplementary criteria)&#xD;
&#xD;
          -  Being responder (= decrease of at least 1 point on the ONLS score after IVIG) and&#xD;
             dependent to IVIG (= increase of at least 1 point on the ONLS score after IVIG&#xD;
             withdrawal or during the tapering period)&#xD;
&#xD;
          -  Having received at least 3 courses of IVIG&#xD;
&#xD;
          -  Negative pregnancy test for women of child-bearing age&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  No social security benefit&#xD;
&#xD;
          -  Pregnancy or intention to become pregnant&#xD;
&#xD;
          -  Nursing mother&#xD;
&#xD;
          -  Recent or active VIH or hepatitis B or C , or lyme infections&#xD;
&#xD;
          -  Monoclonal IgM gammapathy with anti MAG antibodies or CANOMAD syndrome&#xD;
&#xD;
          -  Neutropenia &lt; 1G/L&#xD;
&#xD;
          -  Malignancy during the 10 years before the inclusion&#xD;
&#xD;
          -  Patients having received Mycophenolate&#xD;
&#xD;
          -  History of allergy to mycophenolate or placebo excipient&#xD;
&#xD;
          -  Patients having received immunosuppressive drugs during the 3 months period before the&#xD;
             inclusion&#xD;
&#xD;
          -  Patients receiving : plasma exchange, magnesium hydroxide, aluminium hydroxide,&#xD;
             cholestyramine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Viala, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology - pitié salpetrière hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic inflammatory demyelinating polyradiculopathy</keyword>
  <keyword>intravenous immunoglobulin (IVIG)</keyword>
  <keyword>withdrawal</keyword>
  <keyword>quality of life</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>cost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

